USA - 18 Mar `18Aclaris Therapeutics: ATI-50002

Official Title: A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

In Brief: The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.

Detailed Description: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.

Ages Eligible: 18 Years to 65 Years 

Start Date: March 19, 2018

Completion Date (estimated): September 30, 2019

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03468855
Other Study ID Numbers: ATI-50002-VITI-201

Locations: USA

  • Encinitas, California
  • Los Angeles, California
  • Worcester, Massachusetts
  • Dallas, Texas
  • Lynchburg, Virginia

Contact: To learn more about this study, you or your doctor may contact Aclaris Therapeutics.

FAQOther Questions

  • How can I cure vitiligo?

    There is no cure for vitiligo, but there are a number of effective treatment options that can be discussed with your GP or dermatologist. The aim of treatment is to stop new pat...

  • How long does it take to treat vitiligo?

    Treatment results will vary by person and type of vitiligo. The rule of thumb is that you will need to allow at least 3 to 6 months before you begin to see results from any trea...

  • Shall I take vitamin D for my vitiligo?

    In Brief Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be id...